Participants self-injected themselves with placebo for 4 weeks followed by a 16-week administration of a GHRH analog
Wu Y, Whiteus C, Xu CS, Hayworth KJ, Weinberg RJ, Hess HF, et al
You qualify for the Bridge if you have active Medicare Part D coverage, a BMI of 30 or higher (or 27+ with at least one weight-related comorbidity like type 2 diabetes, hypertension, or sleep apnea), and a prescription from a Medicare-enrolled prescriber
Explore GLP-1 Medications: Mechanisms and Benefits Glucagon-like peptide-1 (GLP-1) treatments represent a significant advancement in managing type 2 diabetes and promoting weight loss
Lee, Molecular and Cellular Biology, DOI: 10.1158/1538-7445.AM2020-1239 Published August 2020